• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

我们准备好申请报销了吗？关于健康技术评估的真实世界证据发展综述：第20部分。

R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 20.

作者信息

Arora Paul, Ramagopalan Sreeram V

机构信息

Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada.

Inka Health, 100 King St. W. Suite 1600, Toronto, ON M5X 1G5, Canada.

出版信息

J Comp Eff Res. 2025 Sep;14(9):e250113. doi: 10.57264/cer-2025-0113. Epub 2025 Jul 23.

DOI:10.57264/cer-2025-0113
PMID:40698536
Abstract

In this update, we examine Canada's Drug Agency position statement on artificial intelligence in evidence generation, a systematic review of clinical trial data linkage approaches, and real-world effectiveness evidence from England's respiratory syncytial virus vaccination program.

摘要

在本次更新中，我们审视了加拿大药品管理局关于人工智能在证据生成方面的立场声明、对临床试验数据关联方法的系统评价，以及来自英格兰呼吸道合胞病毒疫苗接种计划的真实世界有效性证据。

相似文献

1
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 20.我们准备好申请报销了吗？关于健康技术评估的真实世界证据发展综述：第20部分。
J Comp Eff Res. 2025 Sep;14(9):e250113. doi: 10.57264/cer-2025-0113. Epub 2025 Jul 23.
2
Bivalent prefusion F vaccination in pregnancy and respiratory syncytial virus hospitalisation in infants in the UK: results of a multicentre, test-negative, case-control study.英国孕期二价预融合F疫苗接种与婴儿呼吸道合胞病毒住院情况：一项多中心、检测阴性的病例对照研究结果
Lancet Child Adolesc Health. 2025 Jul 18. doi: 10.1016/S2352-4642(25)00155-5.
3
Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study.安大略省老年人接种疫苗预防呼吸道合胞病毒病的影响和成本效益分析：加拿大免疫研究网络（CIRN）研究。
Vaccine. 2024 Mar 7;42(7):1768-1776. doi: 10.1016/j.vaccine.2024.02.041. Epub 2024 Feb 16.
4
Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes.孕期接种呼吸道合胞病毒疫苗以改善婴儿结局。
Cochrane Database Syst Rev. 2024 May 2;5(5):CD015134. doi: 10.1002/14651858.CD015134.pub2.
5
Environmental sustainability in health technology assessment: an analysis of the activities of Canada's Drug Agency and the England's NICE.卫生技术评估中的环境可持续性：对加拿大药品管理局和英国国家卫生与临床优化研究所活动的分析。
Int J Technol Assess Health Care. 2025 Jul 21;41(1):e53. doi: 10.1017/S0266462325100366.
6
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 17.我们准备好申请报销了吗？与卫生技术评估相关的真实世界证据进展综述：第17部分。
J Comp Eff Res. 2025 Jan;14(1):e240212. doi: 10.57264/cer-2024-0212. Epub 2024 Nov 27.
7
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 19.我们准备好申请报销了吗？与卫生技术评估相关的真实世界证据发展综述：第19部分。
J Comp Eff Res. 2025 Jul;14(7):e250063. doi: 10.57264/cer-2025-0063. Epub 2025 May 12.
8
Are current clinical studies on artificial intelligence-based medical devices comprehensive enough to support a full health technology assessment? A systematic review.基于人工智能的医疗器械的当前临床研究是否足够全面，足以支持全面的健康技术评估？系统评价。
Artif Intell Med. 2023 Jun;140:102547. doi: 10.1016/j.artmed.2023.102547. Epub 2023 Apr 23.
9
Budget impact of maternal vaccination with RSVpreF to protect privately insured infants in Dubai against respiratory syncytial virus.使用呼吸道合胞病毒融合前体蛋白（RSVpreF）对迪拜的私人保险婴儿进行母体疫苗接种以预防呼吸道合胞病毒的预算影响。
Hum Vaccin Immunother. 2025 Dec;21(1):2523106. doi: 10.1080/21645515.2025.2523106. Epub 2025 Jul 2.
10
Modelling the epidemiological impact of maternal respiratory syncytial virus (RSV) vaccination in Australia.模拟澳大利亚孕妇呼吸道合胞病毒（RSV）疫苗接种的流行病学影响。
Vaccine. 2024 Dec 2;42(26):126418. doi: 10.1016/j.vaccine.2024.126418. Epub 2024 Oct 17.

本文引用的文献

1
Respiratory syncytial virus: health burden, disease prevention, and treatment-recent progress and lessons learned.呼吸道合胞病毒：健康负担、疾病预防与治疗——近期进展与经验教训
Microlife. 2025 Feb 10;6:uqaf003. doi: 10.1093/femsml/uqaf003. eCollection 2025.
2
Using Generative Artificial Intelligence in Health Economics and Outcomes Research: A Primer on Techniques and Breakthroughs.在卫生经济学与结果研究中使用生成式人工智能：技术与突破入门
Pharmacoecon Open. 2025 Apr 29. doi: 10.1007/s41669-025-00580-4.
3
Linkage of Clinical Trial Data to Routinely Collected Data Sources: A Scoping Review.
临床试验数据与常规收集数据源的关联：一项范围综述
JAMA Netw Open. 2025 Apr 1;8(4):e257797. doi: 10.1001/jamanetworkopen.2025.7797.
4
Early impact of RSV vaccination in older adults in England.呼吸道合胞病毒疫苗对英国老年人的早期影响。
Lancet. 2025 Apr 5;405(10485):1139-1140. doi: 10.1016/S0140-6736(25)00346-0. Epub 2025 Mar 24.
5
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 17.我们准备好申请报销了吗？与卫生技术评估相关的真实世界证据进展综述：第17部分。
J Comp Eff Res. 2025 Jan;14(1):e240212. doi: 10.57264/cer-2024-0212. Epub 2024 Nov 27.